Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions
Lymphoma
Interventions
DRUG

Selinexor, anti-PD-1 antibody and P-GemOx

Selinexor, 40mg, qw, po; Pegaspargase, 2500U/m2, IM, d1; Gemcitabine, 1000mg/m2, i.v., d1, d8; Oxaliplatin, 130mg/m2, i.v., d1; anti-PD1 antibody, 200mg, d2, i.v. (21d cycle);

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT06573151 - Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL | Biotech Hunter | Biotech Hunter